Urology Times ✓

@UrologyTimes · Cranbury, NJ · joined 21 Mar 2012

The Leading News Source for Urologists - https://t.co/hDKngB4IyE Expert clinical analysis. Practice advice. Policy perspectives.

24 617Followers

2 082Following

32 391Posts total

3.5KViews on collected posts

Son gönderiler

Urology Times ✓@UrologyTimes17 Sep

The @FDA has granted Regenerative Medicine Advanced Therapy designation to EG110A, which is under development for neurogenic detrusor overactivity with urinary incontinence. https://t.co/cMybPqMAb4 539 views · 0 likes · 0 reposts · 1 replies Open on X →

Urology Times ✓@UrologyTimes17 Sep

WATCH: Sasha Vereecken, BScN, RN, (@sjvereeck) discusses how patient unawareness rivals diagnostic gaps as a barrier in functional urology. @CU_Urology https://t.co/9Q1RzlSudF 628 views · 1 likes · 1 reposts · 0 replies Open on X →

Urology Times ✓@UrologyTimes16 Sep

The @FDA has granted clearance to the LigaSure RAS Maryland jaw device for use with Medtronic’s Hugo robotic-assisted surgery system. https://t.co/BbEZx4DFQe 781 views · 0 likes · 0 reposts · 0 replies Open on X →

Urology Times ✓@UrologyTimes16 Sep

In the latest episode of The #UroOncMinute, Surena Matin, MD, (@SurenaMatinMD) joins host Adam Weiner, MD, (@Adam_Weiner535) to discuss the use of intraoperative chemotherapy at the time of nephroureterectomy. #UTUC Watch the full episode: https://t.co/zA0PBFZKvY https://t.co/e

1:08

729 views · 0 likes · 0 reposts · 0 replies Open on X →

Urology Times ✓@UrologyTimes15 Sep

WATCH: Andrew Peterson, MD, discusses the quality of life impact of post-cancer incontinence and advances in artificial urinary sphincter technology. @DukeHealth https://t.co/oOfCCIskKa 835 views · 1 likes · 0 reposts · 1 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 5 gönderi, 10K–100K takipçi aralığıyla yan yana. boyutuna göre olağan erişim, çoğundan daha zayıf tepki.

Medyan görüntülenme729bu hesap92410K–100K için medyan

Erişim, %2.96%bu hesap3.62%10K–100K için medyan

Etkileşim, %0.19%bu hesap1.52%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	729	924	0.79×
Erişim (görüntülenme ÷ takipçi)	2.96%	3.62%	0.82×
Etkileşim oranı	0.19%	1.52%	0.12×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

83515 Sep

72916 Sep

781

62817 Sep

539

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.24%15 Sep

0.00%16 Sep

0.00%

0.32%17 Sep

0.19%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes40.0%2 in total

Reposts20.0%1 in total

Replies40.0%2 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.